Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review
Liang Zhao, Jianhao Chen, Yizhen Pang, Kaili Fu, Qihang Shang, Hua Wu, […]
SOFIE gets greenlight from US FDA to proceed to Phase II Pancreatic Cancer Study
Dulles, VA – November 10, 2021 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]
FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?
Katharina Dendl 1,2 Stefan A. Koerber 3,4,5 Clemens Kratochwil 1 Jens […]
SOFIE Submits Investigational New Drug Application to US FDA for Pancreatic Cancer Imaging
Dulles, VA – October 12, 2021 – SOFIE Biosciences (SOFIE), an established US manufacturer and […]
New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress GalleryNew Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress
New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress
Surachet Imlimthan, Euy Sung Moon, Hendrik Rathke, Ali Afshar-Oromieh, Frank Rösch, Axel […]
SOFIE promotes Scott Boller to Chief Financial Officer
SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, has promoted the company’s […]
Dr. Michael E. Phelps Awarded the Pioneer in Medicine Award from the Society of Brain Mapping & Therapeutics
The Society for Brain Mapping and Therapeutics (SBMT), the leading multi-specialty association for Brain Mapping, is […]
SOFIE to Commercially Supply FDA-Approved PYLARIFY® (piflufolastat F 18) Injection
SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, will be commercially […]